Lupin Ltd - LUPIN Share Price

Sector: Pharmaceuticals | ISIN: INE326A01037
₹ 804.50 (0.11%) icon31 May, 2023, 3:46:34 PM
Open
₹ 806.15
Prev. Close
₹ 803.60
Turnover(lac)
₹ 9,027.07
Day's High
₹ 813.00
Day's Low
₹ 801.25
52 Wk High
₹ 813.75
52 Wk Low
₹ 592.90
Book Value
₹ 408.20
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 36,609.78
P/E
86.14
EPS
9.34
Div. Yield
0.50

Lupin Ltd Stock View

info icon
Edit Image
HOLD
Target | 16 May, 2023 742.785 (-7.57%)

Lupin Limited is an India-based pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical... Read More

Lupin Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/31/2023 3:46:34 PM

    ₹ 804.5 0.90 0.11
  • Open
  • ₹ 806.15
  • Prev. Close
  • ₹ 803.6
  • Turnover(Lac.)
  • ₹ 9,027
  • Day's High
  • ₹ 813
  • Day's Low
  • ₹ 801.25
  • 52 Week's High
  • ₹ 813.75
  • 52 Week's Low
  • ₹ 592.9
  • Book Value
  • ₹ 408.2
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 36,609.78
  • P/E
  • 86.14
  • EPS
  • 9.34
  • Divi. Yield
  • 0.5

Lupin Ltd Corporate Actions

25 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Apr , 2023

12:00 AM

25 Jan , 2023

12:00 AM

25 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Oct , 2022

12:00 AM

05 Jul , 2022

12:00 AM

AGM

Announcement date: 05 Jul , 2022

View Details

20 Jul , 2022

12:00 AM

20 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

19 May , 2022

12:00 AM

Dividend

Dividend amount: 4
Announcement date: 19 May , 2022

View Details

Lupin Ltd SHAREHOLDING SNAPSHOT
31 May , 2023 | 10:07 PM

PROMOTER - TOTAL47.08%

Indian: 46.80%

Foreign: 0.2827%

NON-PROMOTER - TOTAL 52.92%

Institutions: 42.53%

Non-Institutions: 10.39%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Lupin Ltd News and Update

Article Image
  • 12 hours ago |
  • 5:41 PM

In 2009, Eli Lily and Merck’s Cetuximab (Erbitux) have been approved by the USFDA.

Image not found
  • IIFL News Service |
  • 29 May, 2023 |
  • 5:39 PM
Article Image
  • IIFL News Service |
  • 25 May, 2023 |
  • 5:32 PM
Image not found
  • IIFL News Service |
  • 23 May, 2023 |
  • 5:30 PM
ad IconAd Image

Lupin Ltd FINANCIALS

Lupin Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Lupin Ltd

  • M D Gupta
  • Chairman (Non-Executive)
  • Nilesh Deshbandhu Gupta.
  • Managing Director
  • Vinita Gupta
  • Director & Chief Executive Off
  • R V Satam
  • Company Secretary
  • Jean-Luc Belingard
  • Independent Director
  • Christine Mundkur
  • Independent Director
  • Ramesh Swaminathan
  • Executive Director & CFO
  • Mark D McDade
  • Independent Director
  • K B S Anand
  • Independent Director
  • Punita Kumar Sinha
  • Independent Director
  • Kamal K Sharma
  • Vice Chairman

Summary

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.Lupin Ltd was incorporated in the year 1983 with the name Lupin Chemicals Ltd. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.In the year 2001, Lupin Laboratories Ltd was amalgamated with the company and the name was changed to Lupin Ltd. They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003,... Read More


Reports by Lupin Ltd


Reports by Lupin Ltd